A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer
/in Hyperthermia, International Publications, NSCLC /von 2020-03-17 / J Adv Res 2020 Jul;24:175-182Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2020-03-16 / Cancer Cell 2020 03;37(3):289-307.e9Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
/in International Publications, IOZK Veröffentlichungen /von 2020-03-16 / Biomedicines 2020 Mar;8(3)Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
/in Dendritic Cells, Hyperthermia, International Publications /von 2020-03-12 / Pharmaceutics 2020 Mar;12(3)Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-03-12 / Front Oncol 2020;10:343Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia
/in Hyperthermia, International Publications /von 2020-03-10 / Front Oncol 2020;10:254New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-03-06 / Biomedicines 2020 Mar;8(3)Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification
/in Breast Cancer, Hyperthermia, International Publications /von 2020-03-06 / Cancers (Basel) 2020 Mar;12(3)Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
/in Dendritic Cells, International Publications /von 2020-03-05 / Cancers (Basel) 2020 Mar;12(3)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de